Pancreatic Ductal Adenocarcinoma research hub
13 indexed studies · 8 currently recruiting
- active not recruitingPHASE2, PHASE3
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
This study is looking at a new drug, Navlimetostat, combined with standard treatment (Nab-paclitaxel and Gemcitabine) for pancreatic cancer that has spread. It's for people whose cancer has a specific genetic change called MTAP deletion, which the new drug targets.
United States · Argentina · Australia - recruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
United States · Canada · China - recruitingPHASE1, PHASE2
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
This study is testing a new drug, ART0380, for people with advanced cancer. It aims to find the safest dose, understand side effects, and see how well it works, both alone and with other treatments like gemcitabine or irinotecan.
United States · France · Spain - recruitingPHASE1, PHASE2
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
This study looks at a new drug, sacituzumab tirumotecan, alone or with other common treatments for advanced bowel, pancreatic, and bile duct cancers. Researchers want to see if it's safe, tolerable, and can shrink these cancers.
United States · Australia · Canada - recruitingPHASE1, PHASE2
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This study is testing a new experimental medicine, AZD5863, for people with advanced stomach, oesophageal, or pancreatic cancer. It aims to see if the medicine is safe, what dose works best, and if it can help fight the cancer.
United States · China · France - recruitingPHASE2, PHASE3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
This study is looking into a new treatment called SBP-101 for advanced pancreatic cancer. It combines SBP-101 with standard chemotherapy (nab-paclitaxel and gemcitabine) to see if it helps people live longer and improves their quality of life.
United States · Australia · Austria - active not recruiting
Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers
This study is looking for better ways to spot pancreatic cancer early. Researchers are collecting urine and blood samples from people with and without pancreatic problems. They hope to find a simple test to help doctors diagnose pancreatic conditions sooner, which could lead to more effective treatment.
United Kingdom - recruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
United States · Australia · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1
This study is looking at a new treatment called NP137 when given alongside a common chemotherapy for pancreatic cancer. It's for adults with a type of pancreatic cancer that hasn't spread far but can't be removed by surgery. The aim is to see if these treatments work well together.
France - ongoing, recruitingTherapeutic exploratory (Phase II)
Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours
This study is testing a new drug for certain advanced cancers, including some pancreatic, lung, and bile duct cancers. Doctors want to see how well the drug shrinks tumours and if it's safe. It's for adults whose cancer has a specific genetic change.
Spain · France · Belgium - authorisedTherapeutic confirmatory (Phase III)
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
This study looks at different ways to give chemotherapy before surgery for pancreatic cancer. We want to see if a shorter or longer course of treatment works better in helping people live longer and preventing the cancer from growing.
Italy - recruitingPHASE1, PHASE2
Study for AZD4360 in Participants With Advanced Solid Tumours
This study is testing a new drug, AZD4360, for people with advanced stomach, bile duct, or pancreatic cancers that have a specific marker called CLDN18.2. It aims to see how safe it is and if it helps shrink tumors.
United States · China · Germany - recruiting
Pancreatic Cancer Early Detection Consortium
This study aims to find better ways to spot pancreatic cancer early, especially in people with a higher risk due to family history or specific genetic changes. Researchers will collect health information and samples over time to understand how the disease develops.
United States · Australia · Canada